MLN 2238 (CAS: 1072833-77-2) inhibits the chymotrypsin-like proteolytic (β5) site of the 20S proteasome with IC50 and Ki of 3.4 nM and 0.93 nM, respectively. MLN2238 has an improved pharmacodynamic profile and antitumor activity compared with bortezomib in both OCI-Ly10 and PHTX22L models. Although both MLN2238 and bortezomib prolonged overall survival, reduced splenomegaly, and attenuated IgG2a levels in the iMyc(Cα)/Bcl-X(L) GEM model, only MLN2238 alleviated osteolytic bone disease in the DP54-Luc model.
|
Technical Data
|
|
Appearance:
|
Off White Solid
|
|
Purity:
|
> 98%
|
|
QC Data:
|
 View Current Lot Data File
|
|
CAS:
|
1072833-77-2)
|
|
Storage
|
-20°C, long term; 4°C, short term
|
|
Shipping
|
Room temperature
|
|
TGF-beta/Smad
Nampt
